216 related articles for article (PubMed ID: 32790610)
21. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs.
Pirozzi Farina F; Pischedda A
Arch Ital Urol Androl; 2016 Jan; 87(4):312-6. PubMed ID: 26766804
[TBL] [Abstract][Full Text] [Related]
22. Atypical post-finasteride syndrome: A pharmacological riddle.
Gupta AK; Sharma N; Shukla P
Indian J Pharmacol; 2016; 48(3):316-7. PubMed ID: 27298504
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia.
Di Loreto C; La Marra F; Mazzon G; Belgrano E; Trombetta C; Cauci S
PLoS One; 2014; 9(6):e100237. PubMed ID: 24959691
[TBL] [Abstract][Full Text] [Related]
24. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
Lee S; Lee YB; Choe SJ; Lee WS
Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
[TBL] [Abstract][Full Text] [Related]
25. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
Shanshanwal SJ; Dhurat RS
Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
[TBL] [Abstract][Full Text] [Related]
26. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
27. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.
Liu L; Zhao S; Li F; Li E; Kang R; Luo L; Luo J; Wan S; Zhao Z
J Sex Med; 2016 Sep; 13(9):1297-1310. PubMed ID: 27475241
[TBL] [Abstract][Full Text] [Related]
28. 5α-Reductase inhibitors in androgenetic alopecia.
Yim E; Nole KL; Tosti A
Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):493-8. PubMed ID: 25268732
[TBL] [Abstract][Full Text] [Related]
29. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation.
Cecchin E; De Mattia E; Mazzon G; Cauci S; Trombetta C; Toffoli G
Int J Biol Markers; 2014 Dec; 29(4):e310-6. PubMed ID: 24855036
[TBL] [Abstract][Full Text] [Related]
30. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?
Arias-Santiago S; Camacho-Martínez FM
Actas Dermosifiliogr; 2016 Nov; 107(9):709-711. PubMed ID: 27436801
[No Abstract] [Full Text] [Related]
31. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
[TBL] [Abstract][Full Text] [Related]
32. Prostate, baldness drugs linked to sexual dysfunction.
Kuehn BM
JAMA; 2012 May; 307(18):1903. PubMed ID: 22570451
[No Abstract] [Full Text] [Related]
33. New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database.
Sessa M; Andersen M
BioDrugs; 2021 Mar; 35(2):215-227. PubMed ID: 33609278
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the clinical indications, adverse drug reactions, and finasteride use in patients with benign prostatic hyperplasia in Poland.
Ząbkowski T
Pharmacol Rep; 2014 Aug; 66(4):565-9. PubMed ID: 24948055
[TBL] [Abstract][Full Text] [Related]
35. Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database.
Cho Y; Bea S; Bae JH; Kim DH; Lee JH; Shin JY
Expert Opin Drug Saf; 2023 Dec; ():1-7. PubMed ID: 38112005
[TBL] [Abstract][Full Text] [Related]
36. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology.
Melcangi RC; Caruso D; Abbiati F; Giatti S; Calabrese D; Piazza F; Cavaletti G
J Sex Med; 2013 Oct; 10(10):2598-603. PubMed ID: 23890183
[TBL] [Abstract][Full Text] [Related]
37. Post-Finasteride Syndrome. Literature Review.
Romero Pérez P
Arch Esp Urol; 2022 Jun; 75(5):382-399. PubMed ID: 35983808
[TBL] [Abstract][Full Text] [Related]
38. Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients.
Melcangi RC; Santi D; Spezzano R; Grimoldi M; Tabacchi T; Fusco ML; Diviccaro S; Giatti S; Carrà G; Caruso D; Simoni M; Cavaletti G
J Steroid Biochem Mol Biol; 2017 Jul; 171():229-235. PubMed ID: 28408350
[TBL] [Abstract][Full Text] [Related]
39. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms.
Ganzer CA; Jacobs AR; Iqbal F
Am J Mens Health; 2015 May; 9(3):222-8. PubMed ID: 24928450
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature.
Busetto GM; Del Giudice F; D'Agostino D; Romagnoli D; Minervini A; Rocco B; Antonelli A; Celia A; Schiavina R; Cindolo L; Chung BI; Kim JH; Maggi M; Sciarra A; De Berardinis E; Porreca A
Arch Ital Urol Androl; 2020 Jan; 91(4):205-210. PubMed ID: 31937082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
